Tempus – Making precision medicine a reality, through the power of artificial intelligence

Precision medicine helps physicians determine more personalized treatments for patients considering individualized approaches instead of a blanketed approach for all patients. With artificial intelligence, it takes precision medicine to the next level and increases the accuracy and prediction of outcome for patients. It is believed that precision medicine is not completely possible without the addition of machine learning algorithms to assist in the process.

Tempus is a technology company that is building the world’s largest library of molecular and clinical data and an operating system to make that data accessible and useful, in an effort to bring the power of artificial intelligence to healthcare.  The firm enables physicians to make real-time, data-driven decisions and deliver personalized care for patients through their interactive analytical and machine learning platform. The main goal of the company is for each patient to benefit from the treatment of others who came before by providing the health care industry with AI tools.

Tools furnished by Tempus to collect, cleanse, and analyze data to find better solutions

Next-Generation Sequencing

Tempus provides a broad range of DNA and RNA sequencing services, generating high quality somatic and germline molecular data along with therapeutic context to empower physicians to make data-driven decisions. Through genomic sequencing, one can identify genomic alterations. Potentially relevant therapies are reported and prioritized based on the strength of the clinical evidence, which establishes the association between genomic alterations and relevant therapeutic options.

Clinical data solutions

Tempus has advanced tools and technologies which convert text buried inside oncology notes, pathology reports, and radiology reports into structured data that can be used for research, analysis, quality metrics reporting, and clinical decision support. The team of trained abstractors uses optical character recognition (OCR), natural language processing (NLP) tools, and automation to structure, clean and standardize data.

Image Analysis and Machine Learning

The quantitative features found in radiology scans and pathology slides alone have the ability to uncover disease characteristics that are invisible to the naked eye. By combining structured radiomics with other orthogonal data in the database, Tempus hope to eventually improve the accuracy of diagnosis and enhance prognosis for patients. This integrated data also supports biomarker development and drug discovery in a research setting.

TIME TRIAL™ program

To date, Tempus has worked to bring over 40 provider networks, with a force of over 1,800 oncologists, into the TIME Trial program, allowing clinical trial access to patients at scale. All Institutions in the network must pass Tempus’ rigorous qualification requirements for rapid activation and investigational-trial readiness.Tempus is changing the paradigm in clinical trial recruitment by rapidly opening pre-vetted TIME Network sites, initiated by the intelligent identification of an eligible patient.

Biological Modelling

At the Tempus|M modeling lab, a state-of-the-art in vitro organoids development and testing facility, use patient-derived biological modeling to help researchers understand the potential effects of the various standard of care, targeted, off-label, and combinatorial therapies.

The ardent visionary behind the triumph of Tempus

Eric Lefkofsky is the founder and Chief Executive Officerof Tempus, a leading provider of technology-enabled precision medicine solutions. He is a founding partner of Lightbank, a venture fund investing in disruptive technology businesses. He is also the co-founder and Chairman of Groupon (NASDAQ: GRPN), a global e-commerce marketplace, and co-founder of Mediaocean, a leading provider of integrated media procurement technology; Echo Global Logistics (NASDAQ: ECHO), a technology-enabled transportation and logistics outsourcing firm; InnerWorkings (NASDAQ: INWK), a global provider of managed print and promotional solutions and a founding investor of Uptake Technologies, a leading predictive analytics platform for the world’s largest industries.

He co-chairs the Mr. Eric Lefkofsky Family Foundation with his wife Liz to advance high-impact initiatives that enhance lives in the communities served. He serves as a Trustee of Lurie Children’s Hospital of Chicago, The Art Institute of Chicago, The Museum of Science and Industry, and World Business Chicago. He is also Chairman of the Board of Trustees of Chicago’s Steppenwolf Theatre Company. He is an adjunct professor at the University of Chicago and author of Accelerated Disruption: Understanding the True Speed of Innovation. He graduated from the University of Michigan and received his Juris Doctor at the University of Michigan Law School.

“We are the collective of our combined knowledge base. Our team has a breadth of expertise, and together, we attack cancer from every direction.”